Rheumatoid arthritis

[1]  P. Lipsky,et al.  Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial , 2018, Arthritis Research & Therapy.

[2]  R. Green,et al.  Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial , 2018, Arthritis care & research.

[3]  P. Emery,et al.  Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[4]  D. Solomon,et al.  Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis , 2017, Arthritis care & research.

[5]  F. Breedveld,et al.  Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases , 2017, Annals of the rheumatic diseases.

[6]  A. Steere,et al.  Two rheumatoid arthritis–specific autoantigens correlate microbial immunity with autoimmune responses in joints , 2017, The Journal of clinical investigation.

[7]  R. Moots,et al.  Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial , 2017, The Lancet.

[8]  P. Tak,et al.  Synovial tissue research: a state-of-the-art review , 2017, Nature Reviews Rheumatology.

[9]  N. Bansback,et al.  Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. , 2017, Annals of Internal Medicine.

[10]  J. Smolen,et al.  Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition , 2017, Arthritis Research & Therapy.

[11]  C. Turesson,et al.  Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors , 2017, The Journal of Rheumatology.

[12]  F. Blanco,et al.  Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study , 2017, Arthritis & rheumatology.

[13]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[14]  T. Grosser.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2017, The New England journal of medicine.

[15]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[16]  A. Feinberg,et al.  DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis , 2017, Arthritis Research & Therapy.

[17]  M. Dougados,et al.  Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[18]  G. Kollias,et al.  Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions , 2017, Nature Communications.

[19]  J. Smolen,et al.  Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria , 2017, Arthritis & rheumatology.

[20]  D. M. van der Heijde,et al.  Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment , 2017, Arthritis & rheumatology.

[21]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[22]  L. Calabrese,et al.  The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management. , 2017, Rheumatic diseases clinics of North America.

[23]  P. Gasque,et al.  Chikungunya Pathogenesis: From the Clinics to the Bench. , 2016, The Journal of infectious diseases.

[24]  M. Konig,et al.  Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis , 2016, Science Translational Medicine.

[25]  L. Klareskog,et al.  The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting , 2016, Nature Reviews Immunology.

[26]  G. Burmester,et al.  Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study , 2016, The Lancet.

[27]  M. Boissier,et al.  Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. , 2016, Joint, bone, spine : revue du rhumatisme.

[28]  D. Mieliauskaitė,et al.  Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis , 2016, The Journal of general virology.

[29]  S. Rantapää-Dahlqvist,et al.  Abdominal obesity, gender and the risk of rheumatoid arthritis – a nested case–control study , 2016, Arthritis Research & Therapy.

[30]  Martin J. Aryee,et al.  High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis , 2016, Genome Medicine.

[31]  L. Christiansen,et al.  University of Southern Denmark Differentially Methylated DNA Regions in Monozygotic Twin Pairs Discordant for Rheumatoid Arthritis An Epigenome-Wide Study , 2016 .

[32]  H. Sayles,et al.  Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans. , 2016, Rheumatology.

[33]  A. Barton,et al.  Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23 , 2016, Genome Biology.

[34]  Javier Martín,et al.  Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. , 2016, Autoimmunity reviews.

[35]  I. McInnes,et al.  Rheumatoid arthritis , 2016, The Lancet.

[36]  Kenneth G. C. Smith,et al.  Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis , 2016, Arthritis & rheumatology.

[37]  J. Norris,et al.  Elevated IgA Plasmablast Levels in Subjects at Risk of Developing Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[38]  G. Canny,et al.  The role of female hormonal factors in the development of rheumatoid arthritis , 2016, Rheumatology.

[39]  E. Tan,et al.  Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor , 2016, The Journal of experimental medicine.

[40]  Yoshiya Tanaka,et al.  Baricitinib for the treatment of rheumatoid arthritis , 2016, Expert review of clinical immunology.

[41]  C. Lewis,et al.  Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis , 2016, RMD Open.

[42]  M. Aringer,et al.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs , 2016, Annals of the rheumatic diseases.

[43]  T. Spector,et al.  Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[44]  R. Landewé,et al.  Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[45]  Wei Wang,et al.  Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes , 2016, Nature Communications.

[46]  Shun-Chiao Chang,et al.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow‐Up: Results From the Nurses’ Health Study , 2016, Arthritis care & research.

[47]  K. Machold,et al.  Efficacy and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort Study , 2016, The Journal of Rheumatology.

[48]  E. Matteson,et al.  An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis , 2016, Genome Medicine.

[49]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[50]  V. Strand,et al.  The changing landscape of biosimilars in rheumatology , 2016, Annals of the rheumatic diseases.

[51]  W. Dixon,et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force , 2016, Annals of the rheumatic diseases.

[52]  E. Karlson,et al.  Post‐Traumatic Stress Disorder and Risk for Incident Rheumatoid Arthritis , 2016, Arthritis care & research.

[53]  Lars Alfredsson,et al.  Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology , 2016, Arthritis & rheumatology.

[54]  P. Taylor,et al.  A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective , 2016, Rheumatology International.

[55]  L. Alfredsson,et al.  Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case–control study , 2015, Annals of the rheumatic diseases.

[56]  Stefan Schoenfelder,et al.  Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci , 2015, Nature Communications.

[57]  L. Klareskog,et al.  Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss , 2015, Annals of the rheumatic diseases.

[58]  M. Radic,et al.  Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms , 2015, Clinical Reviews in Allergy & Immunology.

[59]  J. Smolen,et al.  Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point , 2015, Annals of the rheumatic diseases.

[60]  T. Hsieh,et al.  APLAR rheumatoid arthritis treatment recommendations , 2015, International journal of rheumatic diseases.

[61]  H. Kautiainen,et al.  Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial , 2015, Scandinavian journal of rheumatology.

[62]  J. Smolen,et al.  Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials , 2015, Arthritis Research & Therapy.

[63]  Y. Takasaki,et al.  Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. , 2015, Rheumatology.

[64]  Wei Wang,et al.  DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[65]  A. Ogdie,et al.  Distinctions Between Diagnostic and Classification Criteria? , 2015, Arthritis care & research.

[66]  A. Barton,et al.  Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. , 2015, Biomarkers in medicine.

[67]  Matthias Schneider,et al.  Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT , 2015, Rheumatology.

[68]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[69]  J. Smolen,et al.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges , 2015, Nature Reviews Rheumatology.

[70]  M. Webber,et al.  Nested Case–Control Study of Selected Systemic Autoimmune Diseases in World Trade Center Rescue/Recovery Workers , 2015, Arthritis & rheumatology.

[71]  S. Safiri,et al.  Quality of Life and its Predictors Among Iranian Patients With Rheumatoid Arthritis: A Systematic Review , 2015 .

[72]  T. Huizinga,et al.  Biomarkers for radiographic progression in rheumatoid arthritis. , 2014, Current pharmaceutical design.

[73]  G. Hajishengallis,et al.  Periodontitis: from microbial immune subversion to systemic inflammation , 2014, Nature Reviews Immunology.

[74]  M. Ward,et al.  Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness , 2014, Arthritis care & research.

[75]  D. M. van der Heijde,et al.  A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist , 2014, The Journal of Rheumatology.

[76]  P. Geusens,et al.  Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial , 2014, Annals of the rheumatic diseases.

[77]  L. Alfredsson,et al.  Smokeless Tobacco (Moist Snuff) Use and the Risk of Developing Rheumatoid Arthritis: Results From a Case–Control Study , 2014, Arthritis care & research.

[78]  V. Strand,et al.  Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents. , 2014, Clinical and experimental rheumatology.

[79]  R. Green,et al.  Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. , 2014, Contemporary clinical trials.

[80]  E. Karlson,et al.  Alcohol Consumption and Risk of Incident Rheumatoid Arthritis in Women: A Prospective Study , 2014, Arthritis & Rheumatology.

[81]  P. Mccombe,et al.  Gender differences in autoimmune disease , 2014, Frontiers in Neuroendocrinology.

[82]  L. Klareskog,et al.  Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis , 2014, Nature Reviews Rheumatology.

[83]  G. Firestein.  The disease formerly known as rheumatoid arthritis , 2014, Arthritis Research & Therapy.

[84]  H. Sayles,et al.  Rheumatoid Factor as a Potentiator of Anti–Citrullinated Protein Antibody–Mediated Inflammation in Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[85]  Y. Elserogy,et al.  Assessment of health-related quality of life, anxiety and depression in patients with early rheumatoid arthritis , 2014 .

[86]  M. Sebbag,et al.  IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies , 2014, Annals of the rheumatic diseases.

[87]  R. Buchbinder,et al.  Comparative Effectiveness of Anti–Tumor Necrosis Factor Drugs on Health‐Related Quality of Life Among Patients With Inflammatory Arthritis , 2014, Arthritis care & research.

[88]  D. van Schaardenburg,et al.  Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[89]  P. Tak,et al.  MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial , 2014, Annals of the rheumatic diseases.

[90]  A. Escalante,et al.  Glucocorticoid Dose Thresholds Associated With All‐Cause and Cardiovascular Mortality in Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[91]  P. Emery,et al.  Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial , 2014, The Lancet.

[92]  R. Moots,et al.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study , 2014, Annals of the rheumatic diseases.

[93]  Y. Kwan,et al.  Association between helplessness, disability, and disease activity with health-related quality of life among rheumatoid arthritis patients in a multiethnic Asian population , 2014, Rheumatology International.

[94]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[95]  D. van Schaardenburg,et al.  Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[96]  V. Holers,et al.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. , 2013, Current opinion in immunology.

[97]  B. Combe,et al.  Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort , 2013, Arthritis care & research.

[98]  G. Pruijn,et al.  ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression , 2013, Arthritis Research & Therapy.

[99]  D. M. van der Heijde,et al.  Proposal for a new nomenclature of disease-modifying antirheumatic drugs , 2013, Annals of the rheumatic diseases.

[100]  Tariq Ahmad,et al.  Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway , 2013, Cell.

[101]  C. Huttenhower,et al.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis , 2013, eLife.

[102]  D. M. van der Heijde,et al.  Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) , 2013, Annals of the rheumatic diseases.

[103]  P. Conaghan,et al.  Safety evaluation of leflunomide in rheumatoid arthritis , 2013, Expert opinion on drug safety.

[104]  G. Firestein,et al.  The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[105]  K. Gordon,et al.  SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn’s disease , 2013 .

[106]  T. Pincus,et al.  Decline of Mean Initial Prednisone Dosage From 10.3 to 3.6 mg/day to Treat Rheumatoid Arthritis Between 1980 and 2004 in One Clinical Setting, With Long‐Term Effectiveness of Dosages Less Than 5 mg/day , 2013, Arthritis care & research.

[107]  J. Smolen,et al.  Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review , 2013, Annals of the rheumatic diseases.

[108]  R. Byrne,et al.  Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[109]  C. Schneider,et al.  Biosimilars in rheumatology: the wind of change , 2013, Annals of the rheumatic diseases.

[110]  Martin J. Aryee,et al.  Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in Rheumatoid Arthritis , 2013, Nature Biotechnology.

[111]  C. Allaart,et al.  Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study) , 2013, Annals of the rheumatic diseases.

[112]  T. Glant,et al.  Genetics of Rheumatoid Arthritis — A Comprehensive Review , 2013, Clinical Reviews in Allergy & Immunology.

[113]  D. M. van der Heijde,et al.  Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study , 2013, Arthritis and rheumatism.

[114]  B. Stranger,et al.  Chromatin marks identify critical cell types for fine mapping complex trait variants , 2012, Nature Genetics.

[115]  L. Buitinga.  Valuation of quality of life in rheumatoid arthritis , 2012 .

[116]  T. Huizinga,et al.  Autoimmunity in rheumatoid arthritis: different antigens—common principles , 2012, Annals of the rheumatic diseases.

[117]  V. Strand,et al.  The role of biosimilars in the treatment of rheumatic diseases , 2012, Annals of the rheumatic diseases.

[118]  C. Roux.  Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin , 2012 .

[119]  J. Smolen,et al.  Forget personalised medicine and focus on abating disease activity , 2012, Annals of the rheumatic diseases.

[120]  Eli Stahl,et al.  High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis , 2012, Nature Genetics.

[121]  Georg Schett,et al.  Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment , 2012, Nature Reviews Rheumatology.

[122]  S. Pfeffer,et al.  MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes , 2012, Annals of the rheumatic diseases.

[123]  J. Smolen,et al.  Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[124]  G. Firestein,et al.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis , 2012, Nature Reviews Rheumatology.

[125]  R. Westhovens,et al.  The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo--a population-based study. , 2012, Rheumatology.

[126]  D. Symmons,et al.  Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis , 2012, Arthritis care & research.

[127]  A. Kavanaugh,et al.  Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. , 2012, Clinical and experimental rheumatology.

[128]  J. Smolen,et al.  Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions , 2012, Annals of the rheumatic diseases.

[129]  A. Barton,et al.  Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients , 2012, Annals of the rheumatic diseases.

[130]  M. Dougados,et al.  Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID) , 2012, Arthritis Research & Therapy.

[131]  P. Emery,et al.  Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study , 2012, Annals of the rheumatic diseases.

[132]  B. Haraoui,et al.  Treating Rheumatoid Arthritis to Target: A Canadian Physician Survey , 2012, The Journal of Rheumatology.

[133]  A. Silman,et al.  A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis , 2012, Annals of the rheumatic diseases.

[134]  Peter Kraft,et al.  Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis , 2012, Nature Genetics.

[135]  B. Schwartz,et al.  Patient and Physician Factors Associated With Adherence to Diabetes Medications , 2012, The Diabetes educator.

[136]  J. Smolen,et al.  Inflammatory bone loss: pathogenesis and therapeutic intervention , 2012, Nature Reviews Drug Discovery.

[137]  J. Smolen,et al.  Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index , 2012, Annals of the rheumatic diseases.

[138]  N. de Vries,et al.  Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease , 2012, Annals of the rheumatic diseases.

[139]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[140]  J. Smolen,et al.  Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. , 2011, Arthritis and rheumatism.

[141]  W. Lems,et al.  The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review , 2011, Annals of the rheumatic diseases.

[142]  J. Smolen,et al.  Immediate access rheumatology clinic: efficiency and outcomes , 2011, Annals of the rheumatic diseases.

[143]  Paul Chambers.  Rational use of medicines , 2011, Veterinary Record.

[144]  P. Tugwell,et al.  It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10 , 2011, The Journal of Rheumatology.

[145]  M. Dougados,et al.  Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative , 2011, Annals of the rheumatic diseases.

[146]  P. Kiely,et al.  Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). , 2011, Rheumatology.

[147]  B. Dijkmans,et al.  The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study , 2011, Annals of the rheumatic diseases.

[148]  D. M. van der Heijde,et al.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[149]  C. Bombardier,et al.  Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative , 2011, The Journal of Rheumatology. Supplement.

[150]  T. Therneau,et al.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. , 2011, Arthritis and rheumatism.

[151]  M. Dougados,et al.  Extended Report , 2022 .

[152]  J. Jordan.  Targeted Treatment of the Rheumatic Diseases , 2011 .

[153]  Lars Alfredsson,et al.  Extended Report , 2010 .

[154]  L. Alfredsson,et al.  Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke , 2010, Annals of the rheumatic diseases.

[155]  J. Jacobs,et al.  Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. , 2010, Clinical and experimental rheumatology.

[156]  J. Norris,et al.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. , 2010, Arthritis and rheumatism.

[157]  M. Boers,et al.  Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice , 2010, Annals of the rheumatic diseases.

[158]  Nigel Cox,et al.  Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. , 2010, Rheumatology.

[159]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[160]  Cynthia S Crowson,et al.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. , 2010, Arthritis and rheumatism.

[161]  T. Therneau,et al.  Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. , 2010, Arthritis and rheumatism.

[162]  J. Smolen,et al.  The assessment of disease activity in rheumatoid arthritis. , 2010, Clinical and experimental rheumatology.

[163]  V. Strand,et al.  The impact of rheumatoid arthritis and treatment on patients' lives. , 2010, Clinical and experimental rheumatology.

[164]  P. Kraft,et al.  Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk , 2010, Annals of the rheumatic diseases.

[165]  Soumya Raychaudhuri,et al.  Recent advances in the genetics of rheumatoid arthritis , 2010, Current opinion in rheumatology.

[166]  G. Tobón,et al.  The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. , 2010, Autoimmunity reviews.

[167]  B. Rangan,et al.  Association of periodontitis with rheumatoid arthritis: a pilot study. , 2010, Journal of periodontology.

[168]  G. Burmester,et al.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT , 2010, Arthritis research & therapy.

[169]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[170]  J. Norris,et al.  Identification of undiagnosed inflammatory arthritis in a community health fair screen. , 2009, Arthritis and rheumatism.

[171]  P. Robbins,et al.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints , 2009, Nature Medicine.

[172]  V. Strand,et al.  Use of “spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases , 2009, Annals of the rheumatic diseases.

[173]  M. Daly,et al.  Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk , 2009, Nature Genetics.

[174]  J. Sharp,et al.  Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials , 2009, Annals of the rheumatic diseases.

[175]  A. Boonen,et al.  Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.

[176]  R. Rau,et al.  An update on methotrexate , 2009, Current opinion in rheumatology.

[177]  J. Smolen,et al.  Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. , 2009, Arthritis and rheumatism.

[178]  F. Luyten,et al.  Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial , 2009, Annals of the rheumatic diseases.

[179]  A. Villa,et al.  Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability , 2009, Arthritis research & therapy.

[180]  M. Genovese.  Inhibition of p38: has the fat lady sung? , 2009, Arthritis and rheumatism.

[181]  D. Sugiyama,et al.  Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.

[182]  Stephen Kelly,et al.  Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium , 2009, PLoS medicine.

[183]  Xiayi Ke,et al.  Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13 , 2008, Nature Genetics.

[184]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[185]  L. Klareskog,et al.  Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells , 2008, Annals of the rheumatic diseases.

[186]  Michael Detmar,et al.  Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[187]  D. Strachan,et al.  Rheumatoid arthritis association at 6q23 , 2007, Nature Genetics.

[188]  J. Jacobs,et al.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility , 2007, Annals of the rheumatic diseases.

[189]  Wentian Li,et al.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.

[190]  J. Smolen,et al.  Assessing remission in clinical practice. , 2007, Rheumatology.

[191]  J. Jacobs,et al.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.

[192]  C. Allaart,et al.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[193]  Saskia le Cessie,et al.  A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. , 2007, Arthritis and rheumatism.

[194]  G. Steiner.  Auto-antibodies and autoreactive T-cells in rheumatoid arthritis , 2007, Clinical reviews in allergy & immunology.

[195]  P. Voulgari,et al.  Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. , 2006, Seminars in arthritis and rheumatism.

[196]  Michael M Ward,et al.  Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. , 2006, Arthritis and rheumatism.

[197]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[198]  Karen Kitchen,et al.  Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. , 2005, Arthritis and rheumatism.

[199]  Tanja Stamm,et al.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.

[200]  F. Wolfe,et al.  Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[201]  S. W. Jonsson,et al.  Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36 , 2005, Clinical Rheumatology.

[202]  L. Alfredsson,et al.  Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study , 2004, Annals of the rheumatic diseases.

[203]  Steven J. Schrodi,et al.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. , 2004, American journal of human genetics.

[204]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[205]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[206]  D. C. Schoen.  Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics? , 2003 .

[207]  J. Smolen,et al.  Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.

[208]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[209]  P. Lipsky,et al.  Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. , 2002, Arthritis and rheumatism.

[210]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[211]  J. Ware,et al.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[212]  D. Green,et al.  Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. , 2000, Immunology today.

[213]  J. Esdaile,et al.  Rheumatic diseases in North America's indigenous peoples. , 1999, Seminars in arthritis and rheumatism.

[214]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[215]  F. Breedveld,et al.  Asymptomatic synovitis precedes clinically manifest arthritis. , 1998, Arthritis and rheumatism.

[216]  G. Burmester,et al.  Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. , 1998, Arthritis and rheumatism.

[217]  J. Kriegsmann,et al.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. , 1996, The American journal of pathology.

[218]  A. van der Heide,et al.  The Effectiveness of Early Treatment with Second-Line Antirheumatic Drugs , 1996, Annals of Internal Medicine.

[219]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[220]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[221]  R. Ratner,et al.  Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. , 1993, The American journal of medicine.

[222]  C. Weyand,et al.  The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis , 1992, Annals of Internal Medicine.

[223]  V. Pascual,et al.  Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. , 1992, Journal of immunology.

[224]  M. V. van Leeuwen,et al.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[225]  D. Mccarty,et al.  Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. , 1990, The Journal of rheumatology.

[226]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[227]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[228]  A. Masi.  Articular patterns in the early course of rheumatoid arthritis. , 1983, The American journal of medicine.

[229]  M. Ziff.  Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. , 1974, Arthritis and rheumatism.

[230]  C. Castor,et al.  The microscopic structure of normal human synovial tissue. , 1960, Arthritis and rheumatism.

[231]  J. Scheiman.  NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. , 2016, Journal of clinical gastroenterology.

[232]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[233]  M. Hotopf,et al.  The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism , 2014 .

[234]  N. Bottini,et al.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors , 2013, Nature Reviews Rheumatology.

[235]  J. Singh,et al.  Newer Biological Agents in Rheumatoid Arthritis , 2012, Drugs.

[236]  Rachel Knevel,et al.  Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? , 2011, Rheumatology.

[237]  J. Smolen,et al.  Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. , 2011, Arthritis and rheumatism.

[238]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[239]  Jing Cui,et al.  Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci , 2010, Nature Genetics.

[240]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[241]  G. Schett,et al.  Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. , 2007, Arthritis and rheumatism.

[242]  G. Kobelt,et al.  The burden of rheumatoid arthritis and access to treatment: health burden and costs , 2007, The European Journal of Health Economics.

[243]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[244]  M. Uffmann,et al.  Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis , 2004 .

[245]  A S Rigby,et al.  Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. , 2000, Arthritis and rheumatism.

[246]  M. Weinblatt.  Efficacy of methotrexate in rheumatoid arthritis. , 1995, British journal of rheumatology.

[247]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[248]  F. Breedveld,et al.  Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. , 1995, Arthritis and rheumatism.

[249]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.